In this new Systematic Review and Network Meta-Analysis, Melatonin appears to outperform Donanemab, Lecanemab, Aducanumab and aerobic Exercise in AD patients as discussed here :
pubmed.ncbi.nlm.nih.gov/384...
Here is a relevant quote from the meta analysis :
' The analysis included 10 randomized placebo-controlled trials with 4,599 patients. Although melatonin and aerobic exercise for a short time were significantly more effective than donanemab, lecanemab, aducanumab and placebo in the primary analysis, there was significant heterogeneity. In the sensitivity analysis excluding exercise, melatonin was significantly more effective than donanemab, lecanemab, aducanumab and placebo, with no significant heterogeneity. Aerobic exercise for a short time was significantly less acceptable than donanemab, aducanumab and placebo. Donanemab, lecanemab, and aducanumab were significantly less tolerable than placebo and donanemab and lecanemab were significantly less acceptable than placebo. '
This seems like a testimony to the lack of effective drug treatments for AD. Other studies have also shown benefit from melatonin for AD and PD.
Art